Cancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary.
Genome Integrity and DNA Repair Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary.
Pathol Oncol Res. 2024 Apr 22;30:1611743. doi: 10.3389/pore.2024.1611743. eCollection 2024.
Small cell lung cancer (SCLC) is a highly aggressive type of cancer frequently diagnosed with metastatic spread, rendering it surgically unresectable for the majority of patients. Although initial responses to platinum-based therapies are often observed, SCLC invariably relapses within months, frequently developing drug-resistance ultimately contributing to short overall survival rates. Recently, SCLC research aimed to elucidate the dynamic changes in the genetic and epigenetic landscape. These have revealed distinct subtypes of SCLC, each characterized by unique molecular signatures. The recent understanding of the molecular heterogeneity of SCLC has opened up potential avenues for precision medicine, enabling the development of targeted therapeutic strategies. In this review, we delve into the applied models and computational approaches that have been instrumental in the identification of promising drug candidates. We also explore the emerging molecular diagnostic tools that hold the potential to transform clinical practice and patient care.
小细胞肺癌(SCLC)是一种侵袭性很强的癌症,多数患者在诊断时已发生转移,因此无法通过手术切除。尽管大多数患者对铂类药物治疗有初始反应,但 SCLC 通常会在数月内复发,最终产生耐药性,导致总体生存率较低。最近,SCLC 研究旨在阐明遗传和表观遗传景观的动态变化。这些变化揭示了 SCLC 的不同亚型,每个亚型都具有独特的分子特征。最近对 SCLC 分子异质性的理解为精准医学开辟了潜在途径,使靶向治疗策略的发展成为可能。在这篇综述中,我们深入探讨了在鉴定有前途的药物候选物方面发挥重要作用的应用模型和计算方法。我们还探讨了新兴的分子诊断工具,它们有可能改变临床实践和患者护理。